QMIA: Quantifying and Mitigating Bias affecting and induced by AI in Medicine

MRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

January 31, 2027
Response Due
Active
Status

Opportunity Overview

Artificial Intelligence (AI) has demonstrated exciting potential in improving healthcare. However, these technologies come with a big caveat. They do not work effectively for minority groups. A recent study published in Science shows a widely used AI tool in the US concludes Black patients are healthier than equally sick Whites. Using this tool, a health system would favour White people when allocating resources, such as hospital beds. AI models like this would do more harm than good for health equity. Such inequality goes way beyond racial groups, affecting people with different gender, age and socioeconomics background. Such AI induced bias might come from healthcare data, which significantly lacks data on minorities and embeds decades of health care disparities among different groups of people. The COVID-19 pandemic highlighted this issue, with UK minority groups disproportionately affected by higher infection rates and worse outcomes. Bias may also arise in the design and development of AI tools, where inequalities can be built into the decisions they make, including how to characterise patients and what to predict. For example, the above-mentioned AI tool in the US uses health costs as a proxy for health needs, making its predictions reflect economic inequality as much as care requirements, further perpetuating racial disparities.

However, currently, AI models in medicine are still only measured by accuracy, leaving their impact on inequalities untested. Current AI audit tools are not fit for purpose as they do not detect and quantity bias based on actual health needs. Largely absent are effective tools devised particularly for healthcare for evaluating and mitigating AI induced inequalities. This project aims to develop a set of tools for optimising health datasets and supporting AI development in ensuring equity. Central to the solution is a novel measurement tool for quantifying health inequalities: deterioration-allocation area under curve. This...

This is one of 44 active United Kingdom Pharmaceuticals opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryPharmaceuticals
PublishedSeptember 30, 2023
Procurement stageActive solicitation
Response dueJanuary 31, 2027
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 12, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

Pharmaceutical Wholesale Services
Community Drug and Alcohol Services
Provision of Drug, Alcohol & DNA Testing Services Framework
Personalised Adaptive Medicine
Repurposing Epigenetic Therapy for Hypertrophic Cardiomyopathy to facilitate the innovation and growth of a N.Ireland Cardiac Drug Development Company
Smallpox Vaccine (2026)
Integrated Drug and Alcohol Treatment and Recovery Service
Meningococcal ACWY vaccine (2027)

See every United Kingdom Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Pharmaceuticals intelligence report in your inbox

A personalized report on United Kingdom Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.